Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Supaglutide

A Study of the Efficacy and Safety of Supaglutide in Healthy Participants

Shanghai Yinnuo Pharmaceutical Technology Co. · Phase 1 · Completed · Enrollment 48

NCT03745885

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
0.15mg Supaglutide or placebon/rn/rn/rn/r
0.375mg Supaglutide or placebon/rn/rn/rn/r
0.75mg Supaglutide or placebon/rn/rn/rn/r
1.5mg Supaglutide or placebon/rn/rn/rn/r
3.0mg Supaglutide or placebon/rn/rn/rn/r

Not shown

  • 0.15mg Supaglutide or placebo: endpoint not reported
  • 0.375mg Supaglutide or placebo: endpoint not reported
  • 0.75mg Supaglutide or placebo: endpoint not reported
  • 1.5mg Supaglutide or placebo: endpoint not reported
  • 3.0mg Supaglutide or placebo: endpoint not reported